EZH2

Across TCGA pan-cancer cohorts, EZH2 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated EZH2 data layer compared with 29 for mass-spec protein and 7 for mutation status.

The strongest signal is observed in lung squamous cell carcinoma (LSCC), where higher EZH2 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated EZH2 expression acts as an unfavorable survival marker, although some lineages such as LSCC and LUAD show a favorable association.

LSCC, LUAD, and PDAC are the cancer types where EZH2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LSCC	DFS	Tertile	All	0.856	0.607	.011	31	view →
LUAD	DFS	Median	III,IV	0.981	0.538	.001	28	view →
PDAC	OS	Median	III,IV	0.334	0.968	.004	22	view →
HNSC	DFS	Median	IV	1.000	0.413	.033	2	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

EZH2–LSCC (DFS)

Open the LSCC breakdown →